Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...